top of page

Search Results

Results found for "Addex Therapeutics"

  • Dr. Katarina Nemec | Dr. GPCR Ecosystem

    I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets while performing various cell-based experiments to understand the binding, activation, and signaling of therapeutically

  • Dr. Rosie Dawaliby | Dr. GPCR Ecosystem

    In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases

  • Dr. Stephane Angers | Dr. GPCR Ecosystem

    He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics

  • Eurofins DiscoverX | Dr. GPCR | Dr. GPCR Ecosystem

    Your One-Stop-Shop for GPCR Drug Discovery and Development Researchers developing GPCR-targeted therapeutics 25+ years of expertise and provides you with cell-based assay solutions for basic research through therapeutic Principle of Eurofins DiscoverX Cell-based Assays Whether you are developing small-molecule or biologic therapeutic Product Solutions for more information on GPCR cell-based solutions for basic research, discovery, and therapeutic

  • A Brief History of allosteric modulation with Dr. Arthur Christopoulos | Dr. GPCR Ecosystem

    Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics They explored the evolution of the field, allosteric modulation concepts, and potential therapeutic approaches Arthur will work on designing ligands for specific receptors, aiming to create biased agonists for therapeutic Yamina discussed the potential of autoantibodies and allosteric modulation in the context of disease and therapeutic endogenous allosteric ligands and the possibility of using a neutral allosteric ligand as a preferred therapeutic

  • From Curiosity to Breakthrough: Ajay Yekkirala on GPCR Innovation | Dr. GPCR Ecosystem

    Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics rerouted his path toward a breakthrough GPCR research career The inside story behind founding Blue Therapeutics Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics

  • Session VI | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem

    particular, drives tumor growth via effects on GBM stem cell self-renewal and metabolism, but also has a therapeutically has been particularly interested in the role adhesion GPCRs play in glioblastoma biology and their therapeutic Javitch1,2 1Departments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University , New York, NY 10032; 2Division of Molecular Therapeutics, New York State Psychiatric Institute, New

  • Dr. Stuart Maudsley | Dr. GPCR Ecosystem

    At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

  • Dr. Stuart Maudsley | Dr. GPCR Ecosystem

    At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

  • Dr. Stuart Maudsley | Dr. GPCR Ecosystem

    At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

  • Session III | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem

    technology for high-throughput screening of pharmacological compound libraries to identify potential therapeutic "Ana Lilia Moreno Salinas (2), Arturo Mancini (1), Raida Jallouli (2), Richard Leduc (2) (1)Domain Therapeutics Laurent Sabbagh on the web Domain Therapeutics Characterizing hADGRE5/CD97 Activation and Signaling: Domain Therapeutics North America Inc., Montreal, Quebec, Canada 3.

  • Signals, pH, and Discovery : Cracking GPCR Mysteries with Dr. Ian Chronis | Dr. GPCR Ecosystem

    Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy , and how understanding receptor activity in acidic microenvironments could unlock new therapeutic strategies

  • GPCR Pharmacology, Career Twists & Serendipity with Sokhom Pin | Dr. GPCR Ecosystem

    From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics years of drug discovery research in the pharmaceutical industry, where he works mainly on GPCRs as therapeutic He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general

  • Dr. Lauren M. Slosky | Dr. GPCR Ecosystem

    protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics

  • Yao Lu (Jackie) | Dr. GPCR Ecosystem

    molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics

  • Dr. Aurélien Rizk | Dr. GPCR Ecosystem

    the company's ability to predict the residence time of a ligand and its potential correlation with a therapeutic Therapeutic Effect and Receptor Interactions Aurelien Rizk and Yamina had a detailed discussion about the importance of gaining more information about the therapeutic effect in patients or animals and the They also shared their preference for small molecule therapies over protein therapeutics.

  • Dr. Terry Hébert | Dr. GPCR Ecosystem

    Terry Hébert is a Professor within the Department of Pharmacology & Therapeutics at McGill University

  • Tanishka S. Saraf | Dr. GPCR Ecosystem

    Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes

  • Dr. Jean-Philippe Pin | Dr. GPCR Ecosystem

    biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic

  • Developing a PROTAC to Degrade the Constitutively Active Onco-GPCR in Uveal Melanoma

    of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic

  • irreversible drugs post 2 | Dr. GPCR Ecosystem

    The result: inconsistent exposure, patchy activity, and sometimes, outright therapeutic failure.

  • GPCR Courses

    Measuring and understanding bias helps design drugs that maximize therapeutic benefits while minimizing See- The Importance of Pharmacologic Assays Lecture 2: Drug Disposition in Physiological Tissues as a Therapeutic Lecture 4: Unconventional GPCR Ligands as Drugs Lecture 5: Unique Exploitable GPCR-Ligand Behaviors for Therapeutic

  • Dopamine-Mediated Motor Recovery after Ischemic Stroke

    We hope our research will aid in the development of new therapeutic interventions for the alleviation

  • GPCR Retreat Logo Contest | Dr. GPCR Ecosystem

    embody the multifaceted nature of GPCRs, showcasing their complexity, versatility, and potential for therapeutic

  • Dr. Amynah Pradhan | Dr. GPCR Ecosystem

    Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic

  • The Role of Quantitative Sciences in GPCRs with Dr. Nagarajan Vaidehi | Dr. GPCR Ecosystem

    She has advanced the use of computational methods to meet the challenges of designing therapeutics with

  • Dr. Fiona Marshall | Dr. GPCR Ecosystem

    As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery

  • Illuminating Functional Selectivity and Allosterism at GPCRs.

    He is also an Associate Leader of the Experimental Therapeutics and Metabolism Program and the Director

  • Dr. Brian Arey | Dr. GPCR Ecosystem

    His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics

  • Dr. Brian Arey | Dr. GPCR Ecosystem

    His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics

bottom of page